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Abstract 
In order to improve clinical outcomes for novel drug delivery systems, distinct optimization of size, shape, 
multifunctionality, and site-specificity are of utmost importance. In this study, we designed various 
multivalent elastin-like polypeptide (ELP)-based tumor-targeting polymers in which multiple copies of IL-4 
receptor (IL-4R)-targeting ligand (AP1 peptide) were periodically incorporated into the ELP polymer 
backbone to enhance the affinity and avidity towards tumor cells expressing high levels of IL-4R. Several 
ELPs with different molecular sizes and structures ranging from unimer to micelle-forming polymers were 
evaluated for their tumor accumulation as well as in vivo bio-distribution patterns. Different percentages 
of cell binding and uptake were detected corresponding to polymer size, number of targeting peptides, or 
unimer versus micelle structure. As compared to low molecular weight polypeptides, high molecular 
weight AP1-ELP showed superior binding activity with faster entry and efficient processing in the 
IL-4R-dependent endocytic pathway. In addition, in vivo studies revealed that the high molecular weight 
micelle-forming AP1-ELPs (A86 and A100) displayed better tumor penetration and extensive retention in 
tumor tissue along with reduced non-specific accumulation in vital organs, when compared to low 
molecular weight non-micelle forming AP1-ELPs. It is suggested that the superior binding activities shown 
by A86 and A100 may depend on the multiple presentation of ligands upon transition to a micelle-like 
structure rather than a larger molecular weight. Thus, this study has significance in elucidating the 
different patterns underlying unimer and micelle-forming ELP-mediated tumor targeting as well as the in 
vivo biodistribution. 
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Introduction 
Most anti-cancer drugs used in cancer therapy 
show minimal effects due to poor penetration into 
tumor tissue associated with pathological and physio-
logical components of the tumor microenvironment 
[1]. Tumor environments are characterized by 
abnormal development of vasculature, which leads to 
overproduction of immature vessels and intertumoral 
pressure [2, 3]. Thus, anti-cancer drugs need to 
eliminate tumor cells and bypass the tumor vascular 
network, which involves crossing vessel walls, 
penetrating the interstitial space, and finally reaching 
tumor cells while maintaining an abundant 
concentration. Numerous drug delivery systems and 








an approach to solve the lack of specificity of 
conventional therapeutic drugs [4]. Nanoparticle- or 
macromolecule-based drug carriers can be linked to 
the therapeutic agent covalently and target the 
perivascular tumor region via passive or active 
targeting strategies [5-8]. Excessive leakiness of the 
tumor vasculature with large pores (cut off size ≥ 200 
nm) and poor lymphatic drainage favors selective 
accumulation of macromolecular drug delivery 
systems (micelles, liposomes, gold nanoparticles, etc.) 
in the tumor [9, 10]. Covalent attachment and 
encapsulation with high molecular weight polymers 
can even solubilize hydrophobic drugs and enlarge 
the hydrodynamic radii, which can prevent renal 
filtration and extend the mean residence time of the 
drug [11-13]. 
Moreover, studies have shown that molecular 
weight is a key parameter of the trans-vascular 
transport of therapeutic drugs. It was demonstrated 
that tumor vasculature is less selective than normal 
vasculature due to large pore size, and a 160 KDa 
molecule is more permeable than a 25 KDa molecule 
[14]. Model analysis using available data showed that 
molecules larger than 25 KDa tend to have high tumor 
accumulation [15]. As protein molecular size signifi-
cantly influences biodistribution, precise control of 
molecular size is necessary for optimum targeting. 
Thus, a highly flexible system which can provide 
controllable nature in terms of size, shape, multi- 
functionality, and site-specificity are necessary to 
improve the clinical outcomes of novel drug delivery 
systems. Genetically engineered biopolymers such as 
collagen-like polymers [16], silk-like polypeptides 
(SLPs) [17], extended recombinant polypeptide 
(XTEN) [18], silk-elastin-like polypeptides (SELPs) 
[19], and elastin-like polypeptide (ELP) [20] provide 
unparalleled control over sequence and structure at 
the genetic level. Elastin like polypeptides (ELPs) are 
extensively used for a wide range of applications 
including drug delivery and tissue engineering [21]. It 
consists of pentapeptide sequences repeat VPGXG 
(where X can be any amino acid except proline) 
derived from mammalian tropoelastin [22]. They are 
thermally responsive biopolymers which undergo a 
reversible phase transition at certain temperatures 
referred to as the transition temperature (Tt). Below 
the Tt, they exist as soluble unimer state but above the 
Tt, ELP molecules form insoluble coacervate. By 
substituting the guest residue X with other amino 
acids and by varying the molecular weight or 
concentration of the protein, the Tt can be tailored 
precisely to match the desired purposes [23]. These 
biopolymers can be modified precisely to have 
defined architectures and functional properties based 
on incorporation of targeting ligands or specific site 
for drug conjugation for particular molecular function 
[24-26]. As these polymers are generally synthesized 
in cells (prokaryotes or eukaryotes) and consist of 
natural or unnatural amino acids, they are less toxic 
since they are subjected to specific proteolytic 
mechanisms that leave relatively inert short peptides 
or amino acids [27]. Fusion of other functional 
peptides or protein domains along the coding 
sequences of these polymers maintain its biological 
activity and allow purification with high yield and 
low cost amenable to scale-up in biological systems 
[28, 29]. Thus, pharmacokinetic parameters such as 
biodistribution and clearance rate can be controlled 
based on the molecular weight, which has an impact 
on in vivo drug carrier disposition [30]. Moreover, due 
to thermal responsive phase behavior, ELP can be 
tuned to assemble into nanoparticle-like structures in 
aqueous solution while sustaining the bio-activities of 
the fusion proteins.  
ELP-based nanoparticles have been successfully 
exploited for the delivery of many clinically approved 
chemotherapeutics drugs in preclinical model [21]. 
Elastin-like polypeptide conjugated with anti-cancer 
drugs like doxorubicin or paclitaxel have shown 
promising therapeutic effects in solid tumor models 
including glioblastoma, prostrate and breast cancer 
[31-33]. Incorporation of a targeting peptide onto 
this ELP-chemotherapeutic construct will further 
improve greater drug uptake by tumor cells without 
much adverse effect. 
In this study, we investigated the tumor- 
targeting activity of various ELP polypeptides 
containing IL-4 receptor (IL-4R)-targeting peptides 
(AP1) based on the size and architecture of 
nanoparticles in tumor accumulation as well as 
biodistribution. Previously, we reported that 
[AP1-V12]6, ELP-based polymer consisting of six 
repeats of AP1 increased binding avidity and affinity 
towards IL-4R. The polymer was highly localized to 
IL-4R-expressing tumor tissue after intravenous 
injection and was retained up to 24 h. Moreover, 
[AP1-V12]6 showed higher accumulation in the liver 
and kidney, which may be attributed to its lower 
molecular weight [34, 35]. Thus, various multivalent- 
based AP1- ELP polypeptides containing random 
repetitions of IL-4R- targeting peptide with different 
molecular weights were generated.  
The studies have reported that high molecular 
weight soluble ELPs (more than 70 KDa) were 
retained in the blood for a long time, resulting in 
EPR-based enhancement of tumor accumulation in a 
breast cancer xenograft model, whereas low 
molecular weight soluble ELP (less than 40 KDa) was 
cleared rapidly by the kidneys [21]. Besides the 
molecular weight variation, amino acid sequence and 




nanostructure formation by elastin-like polypeptides 
(ELPs)-based polymers have great impact on their 
pharmacokinetic or biodistribution properties in 
orthotopic breast cancer mice model [36]. The micelle 
forming ELP block copolymer (78 KDa) and a free 
ELP of similar length (74 KDa) shared the similar 
pharmacokinetics or tumor accumulation pattern. But 
long ELPs (74 KDa) displayed higher heart activity 
with half-life of 8.7 h than short ELPs (37 KDa) which 
half-life of 2.1 h. Thus, emphasizing the importance of 
molecular weight in controlling the fate of these 
polymers. Therefore, the physical characteristics and 
in vivo tumor-targeting efficiency in accordance with 
the molecular weights were determined. 
Additionally, we evaluated the different mechanisms 
underlying unimer and micelle-forming ELP- 
mediated tumor targeting as well as biodistribution in 
vivo.  
Results and Discussion  
Design and Synthesis of AP1-ELPs  
The abnormal development of tumor vascular-
ture, and other physio-pathological condition of 
tumor microenvironment hinder the penetration of 
drugs into the tumor tissue results in antitumor drug 
resistance. Thus, a favorable system which can induce 
site-directed delivery of the drug by penetrating 
heterogeneous tumor microenvironments are of great 
importance. Thus, in this study we have generated 
stimulus responsive, multivalent-based tumor 
targeting ELPs with variable architecture, molecular 
weight, physicochemical properties which can 
self-assemble to form diverse structure and analyzed 
its clinical outcomes in terms of particle size, shape, 
multifunctionality, and site directed delivery. As the 
molecular size greatly affects the fate of ELP 
polypeptides in vivo, we evaluated the behaviors of 
five ELPs with different molecular sizes. The five 
polypeptides (E60, A38, A60, A86, and A100) were 
constructed using the recursive directional ligation 
(RDL) method. Figure 1A shows the corresponding 
amino acid sequences of the chimeric polypeptides. 
Devoid of the IL-4R-targeting peptide, E60 was used 
as the non-targeting control. For effective blood 
circulation, all polypeptides were designed to be 
soluble at the physiological temperature. All 
polypeptides were successfully expressed and 
purified with a yield of ~30 mg/L using the inverse 
transition cycling (ITC) method. The size and purity 
of these polypeptides were confirmed by SDS-PAGE, 
followed by copper chloride staining (Figure S1, 
Supporting Information). A faint extra band with a 
size double that of the expected proteins was 
observed in SDS-PAGE, which could be 
attributed to dimer formation caused by the 
presence of Cys residues at the C-terminus. 
Determination of the exact molecular 
weight by MALDI-TOF/TOF MS 
confirmed the protein sizes of E60 (59438.98 
Da), A38 (38170.22 Da), A60 (59846.40 Da), 
A86 (86261.07 Da), and A100 (100485.50 Da) 
respectively (Figure S2A and S2B, 
Supporting Information). 
Thermal Properties and Particle Size 
Determination  
Thermal transition of the samples 
were characterized by measuring the 
optical density (OD) at 350 nm using a 
UV-visible spectrophotometer at a rate of 
1°C/min. Turbidity profiles clearly 
indicated that A38, A60, and E60 exhibit a 
single transition from the soluble unimer to 
the insoluble aggregate form, as shown by 
dramatic increases in OD (Figure 1B, 1C 
and Figure S3, Supporting Information). 
The transition temperatures (Tt; 50% of 
maximum aggregation) were within the 
range of 38-40°C, just above the 
physiological temperature. On the other 
hand, A86 and A100 showed three-step 
 
 
Figure 1. Characterization of ELP and AP1-ELP polypeptides. (A) Schematic representation 
of ELP and AP1-ELPs with corresponding amino acid sequences. Hydrodynamic radius (nm) and 
turbidity profiles of A38 (B), A60 (C), A86 (D), and A100 (E) were monitored at different temperatures. 
Data are represented as mean ± SD (n = 3). 




transitions such as unimer-micelle-aggregate (Figure 
1D, 1E), consistent with ELP block polymers (ELPBC) 
[37, 38]. At a lower temperature, the samples 
remained as soluble unimers (OD 350<0.1). The critical 
micelle temperature (CMT) at which the 
unimer-to-micelle transition occurred was reflected 
by a subsequent increase in the absorbance (OD 
350∼0.1−0.8) with increase in the temperature (Figure 
S4, Supporting Information). A further rise in the 
temperature over its CMT resulted in large 
micron-sized aggregate formations (OD 350∼1.2−1.8).  
Determination of particle size by dynamic light 
scattering (DLS) demonstrated a three-step transition 
behavior consistent with the turbidity profiles. In 
lower temperature below 35.4 °C, A86 occurred as a 
stable unimer with the hydrodynamic radius (Rh) of 
18.7-19.7 nm. The increased in the absorbance (∼0.1 − 
0.8 OD350) indicating the nanoparticle formation was 
observed within the CMT range of 35.4 - 56.4 °C, 
corresponds with slight increase of hydrodynamic 
radius (Rh) range of 21.17 - 62.4 nm due to partial 
transition of the ELP block with low transition 
temperature. Further increase in the temperature 
above CMT (~57.7 - 64.9 °C), triggered inverse 
temperature phase transition of A86 which induced 
the formation of large micrometer-sized aggregates 
(287.5 - 1481.3 nm) (Figure 1D and Figure S4, 
Supporting Information). Likewise, A100 occurred as 
the unimer, with Rh of ~19.14 nm (below 33°C), and 
transition into a micelle, with Rh of 20.2 - 76.01 nm, at 
33.5 - 45.5 °C respectively. The micelle− aggregate 
transition was observed at ∼46.5 - 56.6 °C (255 - 1407.4 
nm) (Figure 1E and Figure S4, Supporting 
Information).  
 At physiological temperature, A86 and A100 
self-assembled to form nanoparticles with a size of 
~25.54±6.4 nm or ~39.3±3.29 nm respectively, (Figure 
1D, 1E) while A60 had a particle size of ~388±19 nm 
(Figure 1C). In addition, E60 and A38 had the particle 
sizes of ~1703 nm and ~1880 nm, respectively, which 
were relatively larger compared to other polypeptides 
(Figure 1B and Figure S3, Supporting information). 
Further increase in the temperature led to micron- 
sized aggregate formation in all cases. Retention of 
nanoparticle-like structures by A86 and A100 up to an 
extended range of temperatures indicated that both 
the polypeptides remained in a nanoparticle formula-
tion upon systemic administration, demonstrating no 
obstruction of blood vessels.  
Stability of nanoparticle formation by A86 and 
A100 were further confirmed using DLS after 24 h 
incubation in 100% mouse plasma at 37°C. An 
insignificant increased of self-assembled nanoparticle 
formation by A86 and A100 clearly revealed that both 
polypeptides can form stable self-assembled micelle 
like structure in the plasma (Figure S5, Supporting 
Information). Likewise, no significant change in the 
hydrodynamic radii of E60, A38 and A60 were 
observed after 24 h incubation in the plasma which 
ensure the stability of polypeptides for longer time in 
physiological condition. SDS-PAGE 
analysis further confirmed the 
stability of these polypeptides in 
the plasma after 24 h (Figure S6, 
Supporting Information).  
To directly visualize the 
structure, size, and shape of the 
polypeptides, Cryo-TEM images 
were taken after incubating the 
proteins at 37°C. The TEM images 
clearly showed that A86 and A100 
retained their spherical micelle-like 
structures with particle diameter 
sizes of 38~40 nm and 42~50 nm 
(Figure 2A), respectively. On the 
other hand, A38 and A60 remained 
in the aggregate form having large 
micron sizes, clearly confirming a 
one-step transition consistent with 
the turbidity profiles and the DLS 
results. Similarly, E60 formed 
large-sized aggregates due to 
higher hydrophobicity and lower 




Figure 2. Structural determination of AP1-ELPs. (A) TEM images of A38, A60, A86, and A100 at 37 °C, scale 
bars, 100 nm. (B) Circular dichroism spectra of polypeptides were taken at different temperatures (20, 25, 30, 35, 
40, 50, and 60 °C). Data are represented as mean ± SD (n = 3).  




Secondary Structure Characterization 
Changes in the secondary structure (helix, beta, 
turn, and random) in response to temperature were 
monitored using circular dichroism (CD). We 
investigated whether the thermal transition and 
different forms of the designed polypeptides 
correlated with the conformational changes. The CD 
spectra of E60 acquired as a function of temperature 
was consistent with ELPs of different length and guest 
residue compositions reported in other studies 
[39-42]. CD spectroscopy of E60 revealed helix 
formation, which was reflected by negative bands at 
208 nm, 222 nm and positive band at 190 nm (Figure 
S7B, Supporting Information). On the other hand, A38 
and A60 showed a gradual deeper negative peak at 
222 nm compared to E60 with subsequent increased in 
temperature which clearly indicates a helix 
conformation (Figure 2B). Increased helix formation 
may be attributed to the presence of multiple copies of 
hydrophilic-targeting ligands (AP1) along the ELP 
backbone. The negative peak of A60, A86 and A100 
were profoundly deeper than that of A38, which may 
be directly correlated with the greater number of 
targeting peptides. The spectra of all the polypeptides 
were characterized by high percentage of random 
coils at lower temperature of 20 °C (Table S1, 
Supporting Information). The consistent gradual 
structural shift from disordered random coiled 
structure to highly ordered β-turn and β-sheet at 
higher temperatures by E60 correspond to the 
structural shift between the soluble monomers to the 
insoluble aggregates with increasing temperature [42, 
43]. Likewise, the targeted polypeptides A38 and A60 
displayed a gradual decrease in random coil 
corresponding to a simultaneous constant increase in 
the β-turn structure conformation. The steady 
increase in β-turn formation caused by A38 or A60 at 
higher temperature correlated with an increased 
turbidity and particle size. Estimation of the mean 
secondary structure contents revealed that the 
appearance of β-sheet at 50°C was consistent with an 
increase in turbidity by A86. At 60°C, we observed a 
predominant existence of β-sheet conformation with 
stable aggregate formation (Table S1, Supporting 
Information). Likewise, β-sheet conformations of 
A100 appeared at 40°C with predominance at 60 °C, 
accompanied with increasing turbidity from 39.67°C. 
Thus, we interpreted that the appearance of ordered 
β-sheet conformations in response to temperature 
correlated with increased turbidity as well as large 
micron-sized aggregate formations.[43] Similar to other 
studies, our study further confirmed that the variation 
in CD spectra occurred in response to temperature 
and directly correlated with increased turbidity [44, 
45]. 
Estimation of Cell binding and Uptake 
To investigate the in vitro cell binding efficacy, 
respective polypeptides were labeled with Alexa-488 
at the C-terminal Cys residue. IL-4R-dependent 
targeting activity was confirmed in 4T1 murine breast 
cancer and MDA MB231 human breast cancer cells 
using the flow cytometry, after treatment for 1 h at 
4°C. All the targeting polypeptides (i.e., AP1-ELPs) 
displayed higher cell binding capacity than the 
non-targeting control E60 in both the cell lines. The 
cell binding activities of A38 and A60 were 44.9% and 
27.3% in MDA MB231 cells, respectively, whereas 
non-targeted E60 showed minimal binding of 2.2% 
(Figure 3A). These results clearly indicated that ELP 
itself did not interact with cells, but instead acts as a 
support for multivalent presentation of targeting 
ligands. A38 showed relatively higher binding than 
A60, indicating that presence of greater number of 
targeting peptides in the polymer backbone with 
increased molecular weight had no effect on 
percentage of binding. The micelle-forming AP1-ELPs 
(i.e., A86 and A100) displayed superior binding 
capacities of 90.5% and 98.1%, respectively, which is 
approximately 2.01±0.13 and 3.3±0.27-fold higher than 
the non-micelle forming AP1-ELPs (A38 and A60). 
The evaluation at 37°C in MDA MB231 cells revealed 
a higher cellular uptake of the targeted AP1-ELPs 
such as A38, A60, A86, and A100, with the 
percentages of 77.3, 68.3, 96.9, and 98.2%, respectively 
(Figure 3B). No significant difference was observed in 
the uptake by MDA MB231 cells treated with 
targeting polypeptides, except for A60 showing a 
nearly 1.13±0.30-fold decreased when compared to 
A38, A86, and A100. Likewise, A86 and A100 showed 
relatively higher binding activities of 16 and 42.4% in 
4T1 cells respectively (Figure S8A, Supporting 
Information) compared to other polypeptides. Further 
analysis of the cellular uptake by 4T1 cells at 37°C 
revealed maximum internalization values of 32.3 and 
58.16% by A86 and A100, respectively, compared to 
non-targeting control or non-micelle forming 
AP1-ELPs (Figure S8B, Supporting Information). 
Differences in the cellular binding and uptake in 
MDA MB231 and 4T1 cells were solely attributed to 
the level of IL-4R expression (data not shown). An 
increase in the molecular weight, along with the 
targeting peptides of the non-micelle forming 
AP1-ELPs (A38, A60), did not increase the binding 
activity, while micelle-forming AP1-ELPs (A86, A100) 
showed maximum accumulation in tumor cells. Thus, 
the maximum uptake displayed by micelle-forming 
A86 and A100 could be attributed to a 
temperature-dependent phase transition, which 
possibly mediates micelle formation along with 
multivalent display of the targeting ligands on the 




exterior enhancing the cellular localization. On the 
other hand, E60 showed minimum uptake, clearly 
demonstrating that internalization of targeting 
polypeptides was highly dependent on IL-4R- 
mediated endocytosis and was not the non-specific 
effect of hyperthermia. 
Mechanism of Cellular Internalization 
Cell binding activity and cellular uptake of 
AP1-ELPs were further examined by confocal micros-
copy. Consistent with the flow cytometry results, all 
targeting polypeptides displayed efficient cellular 
localization and uptake compared to non-targeting 
E60, in both 4T1 and MDA MB231 cells. Interestingly, 
micelle-forming A86 and A100 polypeptides showed 
maximum accumulation and uptake in MDA MB231 
cells compared to other polypeptides (Figure 3C and 
Figure S9, Supporting Information). There was no 
significant difference in cellular accumulation 
between A38 and A60, which suggested that an 
increase in number of targeting peptide was not the 
key factor for the optimal binding. Moreover, an 
increase in the molecular weight in the case of 
non-micelle forming polypeptides such as A60 
resulted in comparatively less accumulation in cells, 
which may be attributed to minimal exposure of the 
targeting ligands. Together, these results suggested 
that the extreme uptake shown by A86 and A100 may 
be due to micelle formation, which might reduce the 
polymer size as well as increase the exposure of 
targeting peptides on the exterior, thereby allowing 
more effective internalization. Similarly, A86 and 
A100 showed maximum accumulation and uptake 
compared to non-micelle forming polypeptides (A38 
and A60) in 4T1 cells (Figure S10 and S11, Supporting 
Information). The molecular weight dependency in 
cellular internalization were not clearly visible under 
in vitro conditions; thus, it was expected that the 
individualized targeting activity displayed by 
respective polypeptides could be due to their 
structure transition in response to the temperature or 
the valance of the targeting ligands constitution upon 
transition. We further examined the subcellular 
localization patterns of the polypeptides and checked 
whether their internalization patterns were truly 
based on ligand-dependent endocytosis or on the 
non-specific effect of hyperthermia. In addition, we 
also monitored the size-dependent subcellular 
localization, since cellular uptake and efficiency of 
processing in the endocytic pathway are dependent 
on particle size [46]. Thus, co-localization of the 
labeled polypeptides in distinct subcellular locations 
such as early endosomes (EEA1) and lysosomes 
(lysotracker) were monitored. The anti-EEA1 staining 
after 30 min of incubation with the polypeptides 
(Figure 4) showed overlapping of red dots (EEA1) 
with green (AP1-ELPs), suggesting rapid localization 
to early endosomes, that subsequently disappeared 
after 1 h (Figure S12, Supporting information). On the 
other hand, yellow spots were observed resulting 
from overlapping of the green with the red signal for 
lysosomes, suggesting polypeptide localization at 
lysosomes after 1 h (Figure 5). Thus, after binding 
with IL-4R, all the polypeptides underwent a 
receptor-mediated endocytic mechanism, which was 
denoted by localization to early endosomes followed 
by movement to lysosomes. A38 and A60 revealed 
maximum co-localization with early endosomes and 
lesser localization to the lysosomes, whereas A86 and 
A100 showed maximum localization with lysotracker 
in a short time period corresponding to minimal 
overlapping with early endosomes, clearly indicating 
faster entry of polypeptides compared to non-micelle 
forming polypeptides. However, no uptake and 
co-localization was observed in the cells incubated 
with E60. These results suggested that the superior 
binding activities shown by A86 and A100 may 
depend on multiple presentation of ligands upon 
transition to a micelle-like structure, rather than an 
increased number of targeting ligands. 
In vivo Biodistribution of AP1-ELPs  
To examine the pharmacokinetic properties, 
biodistribution, and tumor-targeting activities of 
AP1-ELPs in vivo, FPR 675-labeled polypeptides (100 
µM) were injected intravenously into the 4T1 tumor 
xenograft Balb/C wild-type mice. In this study, the 
4T1 tumor xenograft mouse model was used due to its 
property of rapid cell proliferation with the subse-
quent forming of subcutaneous solid tumors within a 
short period. Determination of pharmacokinetic 
properties after intravenous administration revealed 
that all AP1-ELPs polypeptides were readily cleared 
from the circulation (Table S2). The plasma half-life of 
A38 was 60.7±0.31 h, which increased with the higher 
molecular weight A60 (68.6±0.57 h). Thus, we 
observed that the increased molecular weight resulted 
in the increased retention in the blood circulation with 
maximum exposure to tumor tissue [36, 47]. All the 
targeting polypeptides A38, A60, A86 and A100 
displayed maximum half-lifes (60.7 h, 68.6 h, 64.5 h 
and 63.6 h respectively) than non-targeted E60 (25.5 
h). So, it could be interpreted that functionalization of 
ELP with tumor specific ligands facilitated prolong 
circulation of the polypeptides in the blood stream. 
Moreover, A60 exhibited slightly better half-life than 
A86 and A100. Thus, these results suggested that 
besides increased in the molecular weight of poly-
peptides, their structural conformation and size play a 
vital role in determining the fate of polymer [48]. 
In vivo fluorescence images taken by an IVIS in 




vivo imaging system at different time points (10 min, 
1, 2, 4, 6, 12, 24, and 48 h) displayed different patterns 
of time-dependent tumor accumulation and 
biodistribution, and were found to be dependent on 
the molecular weight (Figure 6A). Non-targeting E60 
was observed to accumulate non-specifically in 
off-target tissues. Low molecular weight A38 rapidly 
accumulated as early as 1 h, reaching maximum 
intensity at 2 h, followed by a steady decrease over 
time. In addition, A60 showed a steady increase at 
tumor sites in a time-dependent manner, with 
maximum accumulation at 12 h, which then reduced 
over 48 h (Figure 6B). These data clearly 
demonstrated that an increase in the molecular 
weight resulted in longer retention at the tumor sites 
as well as less non-specific accumulation. 
Furthermore, A86 showed higher accumulation at 10 
min post-injection and persisted until 48 h. This mode 
of accumulation displayed by A86 was likely due to 
its micelle-like formation upon injection rather than 
an increase in molecular weight. Likewise, A100 
showed a similar pattern of accumulation in tumors, 
as evidenced by a gradual increase in the fluorescent 
intensity that was maintained up to 48 h. 
Comparatively, A86 and A100 showed minimum 
off-target tissue accumulation along with relatively 
reduced accumulation in the kidneys, followed by 
rapid degradation over time. 
 
 
Figure 3. Determination of cellular binding and uptake. Histogram represents the percentage of cellular accumulation and uptake determined by flow cytometry after 
MDA MB231 cells were incubated with fluorescent labeled E60, A38, A60, A86, or A100 at 4°C (A) and 37°C (B) for 1 h. Data are represented as the mean ± SD and analyzed 
using one-way ANOVA followed by a Tukey post-hoc test, *P<0.05. (C) MDA MB231 cells were treated with 0.3125 µM of the respective polypeptides labeled with Alexa-488 
at 37°C for 1 h, and observed under confocal laser microscopy. Cell membrane and nuclei were stained with WGA Alexa 594 and Hoechst, respectively. Representative confocal 
images of five independent experiments. Scale bar, 20 µm.  





Figure 4. Examination of subcellular localization. MDA MB231 cells were incubated with 0.3125 µM of the respective polypeptides labeled with Alexa-488 at 37°C for 30 
min and co-localization of polypeptides with early endosomes were observed under confocal laser microscopy. Scale bar, 20 μm. Right panels: Examination of co-localization of 
polypeptides with early endosomes by Z-section scanning of confocal microscopic images. Hoechst: nuclear stain, blue; Red: early endosomes (EEA1); Green: polypeptides 
labeled with Alexa-488. Representative confocal images of 3 independent experiments. Scale bar, 10 µm. 
 
 
Figure 5. Confocal laser scanning microscopic images of MDA MB231 cancer cells treated with 0.3125 µM of respective polypeptides at 37°C for 1 h. Scale bar, 20 μm. Right 
panels: Examination of co-localization of polypeptides with lysosomes by Z-section scanning of confocal microscopic images. Hoechst: nuclear stain, blue; Red: lysotracker; Green: 
polypeptides labeled with Alexa-488. Representative confocal images of three experiments Scale bar, 10 μm. 





Figure 6. In vivo biodistribution imaging of AP1-ELPs in allograft mice model. (A) FPR 675-labeled E60, A38, A60, A86, and A100 (100 µM) were injected 
intravenously into 4T1 tumor allograft mice. The in vivo fluorescence images were collected at different time points (10 min, 1, 2, 4, 6, 12, 24, and 48 h) after intravenous injection 
(IV) to determine biodistribution and a representative image of each group is shown. (B) Quantification of fluorescence intensities in tumor sites at different time intervals. All 
data are presented as mean ± SD (n = 6), statistical significance was determined by one-way ANOVA analysis, (***P<0.001, **P<0.01). (C) Fluorescence intensities of excised 
tumors and organs at 48 h post-injection (n = 10). Data are represented as mean ± SD and analyzed using one-way ANOVA, (n=3), *P<0.05.  
 
Ex vivo fluorescence images of tumors and 
organs isolated at 48 h post-injection from 4T1 
allograft mice further verified that most AP1-ELPs 
were intensely accumulated in tumors, except for E60. 
Consistent with in vivo imaging results, the ex vivo 
images showed similar tumor accumulation patterns. 
The low molecular weight A38 showed a weaker 
signal in tumor tissue after 48 h, with persistent 
increases in the liver and kidneys due to rapid 
degradation (Figure S13C, Supporting Information). 
The higher molecular weight A60 showed relatively 
reduced accumulation in the kidneys, whereas there 
was no significant change in liver accumulation. In 
addition, A86 and A100 displayed maximum tumor 
accumulation and longer retention compared to other 
polypeptides. Fluorescence intensities in the targeted 
tumors increased up to 3.5± 0.07 and 3.8± 0.85 times 
with A86 and A100, respectively, as compared with 
A38 (Figure 6C). Gradual increases in the molecular 
weight and the number of targeting peptides 
considerably reduced liver accumulation. For 
kidneys, 1.2 and 2.45-fold reductions by A86 and 
A100, respectively, were detected in comparison with 
A38. All the polypeptides showed negligible 
accumulation in other organs such as the spleen, 
lungs, and heart. 
Similarly, time dependent tumor accumulation 
studies in 4T1 orthotopic mice model clearly 
confirmed the gradual accumulation of AP1-ELPs at 
tumor site (Figure 7A). The lowest molecular weight 
A38 showed less tumor accumulation than other 
AP1-ELPs. As seen in 4T1 allograft model, A60 
exhibited a rapid increase at tumor sites in a time- 
dependent manner, with maximum accumulation at 
12 h and persisted over 48 h (Figure 7B). Likewise, 
micelle forming AP1-ELPs (A86 and A100) displayed 
significant accumulation in tumor tissue with peaked 
at 12 h. We also observed a gradual decreased in A86 




accumulation from the tumor site over time while in 
the case of A100, the higher signal was retained at 
tumor site for longer time. Interestingly, the tumor 
retention of A60 was significantly higher than A86 at 
24 h and 48 h (Figure 7B) respectively, suggesting that 
apart from the molecular weight of polypeptide, other 
factors such as charge, shape or valence of targeting 
ligands might influence on tumor retention capacity. 
Taken together, these studies demonstrated the 
possible patterns of tumor accumulation by different 
form of targeted based ELPs in both allograft and 
orthotopic mice models. Thus, in future studies, the 
distinctive features of non-micelle or micelle forming 
AP1-ELPs would be exploited for clinical application 
in delivering therapeutic drugs like doxorubicin and 
paclitaxel to target solid tumors. 
Subsequently, the ex vivo fluorescence images of 
tumors and organs from 4T1 orthotopic mice clearly 
revealed maximum tumor retention of A60 and A100 
compared to other polypeptides (Figure 7C and 
Figure S14, Supplementary Information). The low 
molecular weight A38, showed high signal in kidney 
which may be due to rapid clearance of low molecular 
weight through kidney filtration. In contrary, the 
large molecular weight polypeptides A60, A86 and 
A100 showed slightly higher liver uptake, possibly 
due to hepatic clearance over time [36]. Taken 
together, in both the tumor models, the high 
molecular weight AP1-ELPs display better tumor 
penetration with extensive retention in tumor tissue 
along with reduced non-specific accumulation in the 
vital organs. Furthermore, immunohistology 
examination of tumor tissues obtained from 48 h 
post-administration of ELPs in 4T1 allograft mice 
confirmed that A86 and A100 were significantly 
confined to the tumor tissues even after 48 h, as 
compared to other polypeptides (Figure 8). 
 
 
Figure 7. In vivo biodistribution of AP1-ELPs in orthotopic mice model. (A) FPR 675-labeled E60, A38, A60, A86, and A100 (100 µM) were injected intravenously into 
4T1 tumor bearing orthotopic mice after five days of implantation. The representative IVIS images were collected at different time points were shown. (B) The fluorescence 
intensities in tumor sites was determined at different time points (0, 6, 12, 24, 48 h) respectively. The data presented as mean ± SEM (n=3), the statistically significance were 
calculated using one-way ANOVA with Bonferroni correction. **P<0.01, *P<0.05 (C) Histogram represents the fluorescence intensities of excised tumors and organs after 48 h 
post-injection. All Data were represented as mean ± SD (n = 3) and analyzed by one-way ANOVA, *P<0.05. 





Figure 8. Immunohistology staining of tumor tissues extracted from 4T1 tumor xenograft mice after 48 h post-intravenous injection of respective polypeptides. Tumor tissue 
sections were stained with anti-IL-4R and observed under a confocal microscope. Representative images of 10 repetitive experiments. Blue, nuclei stained with DAPI; Green, 
tumor cells stained with anti-IL-4R; Red, labeled polypeptide. Scale bar, 50 µm. 
 
Conclusion 
Taken together, our results collectively verified 
that a multivalent ELP-based delivery system has 
excellent tumor-targeting potential. The molecular 
weight and structural conformation of the 
polypeptides play vital roles in determining tumor 
penetration, biodistribution, as well as retention time 
in tumor tissue. For the first time, we evaluated the 
biodistribution patterns of micelle-forming and 
non-micelle-forming targeting ELP polymers. Based 
on the cellular binding and internalization assay, we 
confirmed that the micelle forming polypeptides 
displayed superior cellular accumulation and uptake 
than non-micelle forming polypeptides. Determina-
tion of targeting activity in vivo in two different mice 
model further confirmed that the high molecular 
weight micelle-forming targeting AP1-ELPs have 
great potential as carriers, in terms of tumor 
localization as well as retention. At the same time, 
these approaches are further optimized for the 
delivery of various therapeutic drugs for clinical 
applications. The mechanisms of drug accumulation 
and release as well as comparison of the therapeutic 
effects between micelle-forming and non-micelle- 
forming AP1-ELPs in association with small 
molecular drugs will be elucidated. As IL-4R is 
overexpressed in different types of the solid tumor, 
we believed that these AP1-ELPs would provide a 




Synthetic oligonucleotides encoding monomer 
genes of V7, V3G3A3, and AP1-V5 were obtained from 
Macrogen Inc. Seoul. All the restriction enzymes were 




purchased from New England Biolab. The competent 
BL21 (DE3) E. coli cells and DH5α were procured from 
Invitrogen, Carlsbad, CA, USA. Circle grow media 
(MP Biomedicals, CA, USA), 100 μg mL-1 of 
ampicillin (AMRESCO, LLC, OH, USA) and 1 mM 
IPTG (Carbosynth Limited, Berkshire, UK) were used 
for protein expression. Sodium chloride and copper 
chloride were acquired from Sigma Aldrich, St. Louis, 
MO, USA. Flamma 675 Vinylsulfone was obtained 
from BioActs, Incheon, Korea. Sulfo-SMCC 
(succinimide 4-[N-maleimidomethyl] cyclohexane 
carboxylate) and other chemicals are acquired from 
Sigma Aldrich. 4T1 murine breast cancer cells and 
MDA MB231 human breast cancer cells were obtained 
from the American Type Culture Collection (ATCC). 
4T1 cells were grown in RPMI-1640 (Hyclone), and 
MDA MB231 cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10 % 
fetal bovine serum (Sigma Aldrich), 100 U/mL of 
penicillin, and 100 μg/mL of streptomycin (Hyclone). 
Cells were maintained at 37 °C containing 5% CO2. 
ELP Nomenclature 
ELPs were designated as ELP [XaYbZc]n, where 
X, Y, Z specify the guest residue, a, b, and c are the 
numbers of corresponding guest residue repeats, and 
‘n’ denotes the number of monomer gene repeats for 
RDL. For example, V3G4A consists of seven 
pentapeptide XGVPG repeats with Valine, Glycine, 
and Alanine as guest residues (X). To avoid confusion, 
we named the ELP and AP1-ELPs according to their 
molecular weight. The estimated molecular weight of 
non-targeting (V3G3A1)16(V7)5 was 60 KDa and thus 
termed as E60. Similarly, targeting polypeptides con-
taining AP1 peptides [(AP1V5)V7]6, (AP1V5)8(V3G3 
A1)12, (AP1V5)16-[(V3G3A1)3V7]3, and (AP1V5)16(V3G3 
A1)12(V7)5 were abbreviated as A38, A60, A86, and 
A100, respectively. 
Thermal Characterization of ELPs 
The transition temperatures (Tt) of E60, A38, 
A60, A86, and A100 were determined by monitoring 
the turbidity profile of protein solutions as a function 
of temperature, using a UV-visible spectrophotometer 
(Agilent Technologies, CA, USA) at 350 nm. 
Absorbance was monitored at 25 μM concentration, 
from 20 ºC to 55 ºC with 1ºC/min increments. The first 
derivative of the turbidity profile with respect to 
temperature was numerically calculated, and the Tt 
was defined as the solution temperature at 50% of 
maximum turbidity.  
Dynamic Light Scattering (DLS) 
Particle sizes of E60, A38, A60, A86, and A100 
were measured in the temperature range 20°C to 
55°C, at increments of 1°C/min, using a Wyatt 
dynaPro NanoStar (Wyatt technology, Santa Barbara, 
CA, USA). The size distribution of the hydrodynamic 
radius was determined by a DLS detector at 90°.  
Cryo-TEM Imaging 
For accurate confirmation of particle size, 
cryo-TEM images were taken using FEI Tecnai 
transmission electron microscope (Oregon, USA). 
Filtered protein samples (25 μM) were incubated at 37 
°C for 10 min, and a small drop of protein was 
air-dried on carbon-coated copper grids for 5 min, 
followed by observation under Cryo-TEM after 
negative staining with uranyl acetate. 
Circular Dichroism Spectra (CD) 
Circular dichroism (CD) spectroscopy was used 
to investigate the secondary structures of the 
polypeptides according to temperature. The CD 
spectra were examined on a Jasco-1500 circular 
dichroism spectrometer (JASCO, Maryland). Protein 
samples were diluted to 25 μM in PBS and filtered 
through a 0.2-μm Whatman syringe filter (GE 
Healthcare, Amersham, UK) to remove impurities. 
The CD spectra were measured at the different 
temperatures of 20, 25, 30, 35, 40, 50, and 60 °C in a 
0.1-cm path length cell. The spectra were recorded 
from 180 to 260 nm at a scan speed of 50 nm/min. 
Flow Cytometry 
4T1 and MDA MB231 cells were used to observe 
the binding activities of the respective polypeptides. 
A total of 1 x 106 cells was incubated with 0.3125 μM 
Alexa 488-labeled polypeptides for 1 h at 4 °C and 37 
°C. The cells were further washed three times with 
PBS and suspended in 300 μL of PBS. The percentages 
of binding were analyzed by flow cytometry (BD 
Bioscience, San Jose, CA, USA). Ten thousand events 
were collected for each sample for the analysis. 
Confocal Microscopy 
4T1 and MDA MB231 (1 x 105) cells were seeded 
on a 4-well chambered slide and grown to 80% 
confluence. Cells were then incubated with 0.3125 μM 
Alexa 488-labeled polypeptides for 1 h at 4 °C and 37 
°C. Cells were washed with PBS and fixed with 4 % 
paraformaldehyde (Sigma Aldrich). Cells were 
immediately observed using a Zeiss LSM-510 Meta 
confocal microscope after nuclei and plasma 
membranes were stained with Hoechst and Wheat 
Germ Agglutinin for 10 min.  
Lysosome and Early Endosome Staining 
MDA MB231 cells were seeded on a cover glass 
inside a 6-well chambered dish filled with appropriate 
culture media. After 24 h, cells were incubated with 
Alexa-488-labeled respective ELPs (0.3125 μM) for 1 h 




at 37 °C. Cells were washed with PBS and further 
incubated with pre-warmed culture medium 
containing lysotracker deep red (Molecular Probes, 
Life Technologies Corporation, Eugene, OR, USA). 
Later, the cells were fixed with 4 % paraformalde-
hyde, nuclei-stained with Hoechst, and observed 
under a confocal microscope. For early endosome 
staining, cells were seeded on a 4-well chambered 
slide to 80% confluence. Cells were then treated with 
respective ELPs for 30 min or 1 h. Early endosomes 
were stained by anti-EEA1 (BD Biosciences, Franklin 
Lakes, NJ, USA) for 1 h at 37 °C, followed by Alexa 
Flour-594 goat anti-mouse IgG (Life Technologies 
Corporation, Eugene, OR, USA) secondary antibody 
for 1 h. The cells were observed under a confocal 
microscope after nuclei were stained with Hoechst. 
In vivo Fluorescent Imaging  
All animal experiments were conducted 
according to the guidelines of the Animal Care and 
Use Committee of Kyungpook National University 
(Permit Number KNU 2018-0017). Athymic wild-type 
mice (BALB/c) were housed in a specific 
pathogen-free environment. Tumors were created by 
subcutaneously injecting 4T1 cells (5 ×106 cells) into 
the right flanks of 6-week-old female mice to generate 
allograft mice. For orthotopic mice model, 5×105 of 
4T1 cells were implanted into left and right mammary 
fat pad and allow to grow for 5 days before imaging. 
The length (a) and width (b) of each tumor were 
measured using a caliper in order to calculate tumor 
volume (mm3) by following formula. V=ab2/2; 
a=length, b= width 
When the tumors reached nearly 200 mm3 in 
volume, the mice were administered 100 µM 
FPR-675-labeled E60, A38, A60, A86, and A100 
intravenously (n=10). In vivo biodistribution was 
monitored at various time intervals of 10 min, 1, 2, 4, 
6, 12, 24, and 48 h post-injection by fluorescence 
imaging (FLI) using an IVIS In vivo Imaging system 
(Perkin Elmer, USA). Grayscale photographic images 
and fluorescence images were superimposed using 
LIVINGIMAGE (version 2.12, Perkin Elmer) and 
IGOR Image Analysis FX software (WaveMetrics, 
Lake Oswego, OR). Fluorescence images were 
obtained at suitable wavelength and spectral 
unmixing (using LIVINGIMAGE software) were done 
to remove the nonspecific FLI signals. Fluorescent 
signals (FLI) were expressed in units of total radiant 
efficiency. All mice were anesthetized using 1% to 2% 
isoflurane gas during imaging. 
Ex vivo Imaging and Immunohistochemistry 
To analyze ex vivo organ distribution, animals 
were euthanized at 48 h post-injection with CO2. All 
the major organs (liver, kidneys, spleen, heart, and 
lungs) along with the tumor tissues were isolated, and 
ex vivo fluorescence images were taken (n = 10). 
Tumor tissues were further fixed with 4 % 
paraformaldehyde overnight and rapidly frozen. 
Tissue slices (8-μm thick) were prepared using a 
cryo-microtome and stained with anti-IL-4R antibody 
(R&D Systems; 1:100), followed by Alexa 488-labeled 
goat anti-mouse IgG secondary antibody (1:200). 
Further tumor accumulation of respective 
polypeptides was observed under a confocal 
microscope after nuclei were stained with DAPI. 
Statistical Analysis 
The statistical significance was determined using 
one-way ANOVA for comparison of multiple groups 
followed by a Tukey post-hoc test. All data analysis 
was carried out by Graph pad prism 6.0 software. 
***P<0.001, **P<0.01, and *P<0.05 were considered as 
statistically significant and indicated by asterisks in 
the figures.  
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